These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17631933)

  • 21. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    Kaiser SM; Emerman M
    J Virol; 2006 Jan; 80(2):875-82. PubMed ID: 16378989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages.
    Hou W; Wang X; Ye L; Zhou L; Yang ZQ; Riedel E; Ho WZ
    J Virol; 2009 Apr; 83(8):3834-42. PubMed ID: 19193806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The viral infectivity factor (Vif) of HIV-1 unveiled.
    Rose KM; Marin M; Kozak SL; Kabat D
    Trends Mol Med; 2004 Jun; 10(6):291-7. PubMed ID: 15177194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emerging role of innate immunity in protection against HIV-1 infection.
    Lehner T; Wang Y; Pido-Lopez J; Whittall T; Bergmeier LA; Babaahmady K
    Vaccine; 2008 Jun; 26(24):2997-3001. PubMed ID: 18180080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.
    Bogerd HP; Wiegand HL; Doehle BP; Cullen BR
    Virology; 2007 Aug; 364(2):486-93. PubMed ID: 17434555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and regulation of antiviral protein APOBEC3G in human neuronal cells.
    Wang YJ; Wang X; Zhang H; Zhou L; Liu S; Kolson DL; Song L; Ye L; Ho WZ
    J Neuroimmunol; 2009 Jan; 206(1-2):14-21. PubMed ID: 19027180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human cellular restriction factors that target HIV-1 replication.
    Strebel K; Luban J; Jeang KT
    BMC Med; 2009 Sep; 7():48. PubMed ID: 19758442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. APOBEC-mediated interference with hepadnavirus production.
    Rösler C; Köck J; Kann M; Malim MH; Blum HE; Baumert TF; von Weizsäcker F
    Hepatology; 2005 Aug; 42(2):301-9. PubMed ID: 16025511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
    Chiu YL; Greene WC
    Annu Rev Immunol; 2008; 26():317-53. PubMed ID: 18304004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
    Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short Communication: Expression of APOBEC3G and Interferon Gamma in Pleural Fluid Mononuclear Cells from HIV/TB Dual Infected Subjects.
    Toossi Z; Meng Q; Aung H; Liu S; Mayanja-Kizza H; Hirsch CS
    AIDS Res Hum Retroviruses; 2015 Jul; 31(7):692-5. PubMed ID: 25924204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vif and Apobec3G in the innate immune response to HIV: a tale of two proteins.
    Farrow MA; Sheehy AM
    Future Microbiol; 2008 Apr; 3(2):145-54. PubMed ID: 18366335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights into cellular microRNAs and human immunodeficiency virus type 1 (HIV-1).
    Kumar A; Jeang KT
    J Cell Physiol; 2008 Aug; 216(2):327-31. PubMed ID: 18452151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 replication in monocyte-derived dendritic cells is stimulated by melarsoprol, one of the main drugs against human African trypanosomiasis.
    Barat C; Pepin J; Tremblay MJ
    J Mol Biol; 2011 Jul; 410(5):1052-64. PubMed ID: 21763506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protecting APOBEC3G: a potential new target for HIV drug discovery.
    Stopak K; Greene WC
    Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The restriction of zoonotic PERV transmission by human APOBEC3G.
    Jónsson SR; LaRue RS; Stenglein MD; Fahrenkrug SC; Andrésdóttir V; Harris RS
    PLoS One; 2007 Sep; 2(9):e893. PubMed ID: 17849022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary culture of human blood-retinal barrier cells and preliminary study of APOBEC3 expression: an in vitro study.
    Lin H; Zhang Z; Zhang H; Yan P; Wang Q; Bai L
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4436-43. PubMed ID: 19369234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 Vif and APOBEC3G: multiple roads to one goal.
    Goncalves J; Santa-Marta M
    Retrovirology; 2004 Sep; 1():28. PubMed ID: 15383144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.
    Rose KM; Marin M; Kozak SL; Kabat D
    AIDS Res Hum Retroviruses; 2005 Jul; 21(7):611-9. PubMed ID: 16060832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.